A randomized phase II trial of gemcitabine, nab-paclitaxel, cisplatin with or without a medically supervised ketogenic diet for patients with metastatic pancreatic cancer.

Cancer · 2026 · PMC12980701 · PMID 41817106

Europe PMC DOI

hedged sentence

0.1100

closest p · 2.2× alpha

0.1100

boldest claim

The sentences

did not reach statistical significancep = .110not close (p > 0.1)

More patients on the MSKD arm achieved a best overall response of partial response (PR) compared to the non‐MSKD arm, but this did not reach statistical significance (68.8% versus 31.2%, p = .110) (Table 3 ).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.